All Releases
View Summary Celldex Therapeutics Presents Data Supporting the Clinical Development of Glembatumumab Vedotin and the Preclinical CD40 Program at the AACR Annual Meeting 2016
Apr 20, 2016
PDF 23.1 KB Add to Briefcase
View Summary Celldex Therapeutics Presents Favorable Safety Profile and Immune Response Data from Phase 1/2 Study of Varlilumab and Nivolumab at the AACR Annual Meeting 2016
Apr 18, 2016
PDF 30.5 KB Add to Briefcase
View Summary Celldex Therapeutics to Present New Clinical and Preclinical Data at the AACR Annual Meeting 2016
Mar 17, 2016
PDF 21.9 KB Add to Briefcase
View Summary Data Safety and Monitoring Board Recommends Celldex's Phase 3 Study of RINTEGA® (rindopepimut) in Newly Diagnosed Glioblastoma be Discontinued as it is Unlikely to Meet Primary Overall Survival Endpoint in Patients with Minimal Residual Disease
Mar 7, 2016
PDF 22.1 KB Add to Briefcase
View Summary Celldex Therapeutics to Present at the Cowen and Company 36th Annual Health Care Conference
Mar 3, 2016
PDF 17.3 KB Add to Briefcase
View Summary Celldex Reports Fourth Quarter and Year-End 2015 Results
Feb 25, 2016
PDF 44.4 KB Add to Briefcase
View Summary Celldex Presents Preliminary Cohort Data from Pilot Study of CDX-301 in Allogeneic Hematopoietic Stem Cell Harvest at the 2016 BMT Tandem Meeting
Feb 20, 2016
PDF 23.4 KB Add to Briefcase
View Summary Celldex to Report Fourth Quarter and Year-End 2015 Business/Financial Results and Host 2016 Corporate Strategy Conference Call
Feb 18, 2016
PDF 18.4 KB Add to Briefcase
View Summary Celldex Therapeutics to Present at the Leerink Partners 5th Annual Global Healthcare Conference
Feb 4, 2016
PDF 17.1 KB Add to Briefcase
View Summary Celldex Therapeutics Initiates Phase 1/2 Study of Varlilumab in Combination with Atezolizumab in Renal Cell Carcinoma
Dec 8, 2015
PDF 26.0 KB Add to Briefcase
View Summary Long-term Survival Benefit Demonstrated in Phase 2 ReACT Study of RINTEGA(R) in Recurrent Bevacizumab-naive Glioblastoma
Nov 20, 2015
PDF 34.8 KB Add to Briefcase
View Summary Celldex Presents Varlilumab Mechanism Data at SITC Annual Meeting 2015
Nov 6, 2015
PDF 29.8 KB Add to Briefcase
View Summary Celldex Reports Third Quarter 2015 Results
Nov 5, 2015
PDF 39.8 KB Add to Briefcase
View Summary Celldex Therapeutics to Present at the Leerink Partners Immuno-Oncology Roundtable
Sep 30, 2015
PDF 22.1 KB Add to Briefcase
View Summary Celldex Reports Second Quarter 2015 Results
Aug 10, 2015
PDF 41.5 KB Add to Briefcase
View Summary Celldex to Report Second Quarter 2015 Financial Results and Host Corporate 2015 Objectives Update Call
Aug 4, 2015
PDF 22.5 KB Add to Briefcase
View Summary Celldex Therapeutics to Present at the Cantor Fitzgerald Inaugural Healthcare Conference
Jul 2, 2015
PDF 21.9 KB Add to Briefcase
View Summary Celldex Therapeutics Appoints Richard Wright as Chief Commercial Officer
Jul 1, 2015
PDF 27.0 KB Add to Briefcase
View Summary Independent Data Safety and Monitoring Board Recommends Continuation of Celldex's Phase 3 Study of RINTEGA(R) (rindopepimut) in Newly Diagnosed Glioblastoma
Jun 29, 2015
PDF 26.9 KB Add to Briefcase
View Summary Randomized Phase 2 ReACT Study of RINTEGA(R) in Recurrent Bevacizumab-naive Glioblastoma Demonstrates Statistically Significant Overall Survival and Emergence of Long-term Survival Benefit; Primary Endpoint of PFS6 Met
May 31, 2015
PDF 39.9 KB Add to Briefcase
Showing 21-40 of 142 Page: 1 2 3 4 5 6 ... 8  Previous 20 | Next 20
Showing 21-40 of 142
Page: 1 2 3 4 5 6 ... 8
 Previous 20 | Next 20
Add to Briefcase = add release to Briefcase